Clinical trial
Pegfilgrastim PBPC Mobilization Study
NCT00066092 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00066092 |
|---|---|
| Title | Pegfilgrastim PBPC Mobilization Study |
| Official title | Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology, Oncology |
| Intervention type | Drug |
| Interventions | pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg |
| Enrollment | 41 |
| Start date | Apr 1, 2003 |
| Primary completion | Mar 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Aug 5, 2003 |
| Last update posted | Feb 28, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: